Literature DB >> 17364191

British and Canadian views on the ethics of paediatric clinical trials.

H M Sammons1, J Malhotra, I Choonara, D S Sitar, D Matsui, M J Rieder.   

Abstract

BACKGROUND: Ethical problems are quoted as a reason not to perform clinical trials in children. Little is known about the views of researchers regarding ethics.
OBJECTIVES: A pilot study was conducted to assess the applicability of a questionnaire design containing trial scenarios to examine views regarding the use of children in drug trials and to elicit possible international differences.
SETTING: Paediatricians and researchers in the United Kingdom and Canada.
METHODS: Responders were presented with a questionnaire containing direct questions and six trial scenarios, each containing an ethical dilemma. Responders were asked regarding their own approval and their perceived opinion of whether an ethical review board (ERB) would approve.
RESULTS: One hundred questionnaires (50 each country) were received. Few responders had research ethics training (14% United Kingdom and 8% Canada). Most (80 and 88%) felt children could be harmed by participation in trials and half (47 and 59%) felt children should only participate if they receive direct benefit. Many (58 and 61%) disagreed with payments beyond travel expenses. In the trial scenarios, 34% of responders were willing to enter healthy children in a pharmacokinetics study of an antibiotic for cystic fibrosis and 22% considered their ERBs would approve. Only a third (33%) would enter children in an analgesia trial that was placebo-controlled.
CONCLUSION: Using healthy children and placebos in trials caused concern. Similar views were found between the two countries. The majority had no training in research ethics. The study highlights the usefulness of a questionnaire with clinical trial scenarios to try to elicit views on the ethics of conducting research in children.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17364191     DOI: 10.1007/s00228-007-0281-9

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Unlicensed and off label prescribing of drugs in general practice.

Authors:  J McIntyre; S Conroy; A Avery; H Corns; I Choonara
Journal:  Arch Dis Child       Date:  2000-12       Impact factor: 3.791

2.  Unlicensed and off label drug use in neonates.

Authors:  S Conroy; J McIntyre; I Choonara
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-03       Impact factor: 5.747

3.  Use of healthy children as volunteers in drug studies: the ethical debate.

Authors:  Gideon Koren; Gregory L Kearns; Michael Reed; Gerrard Pons
Journal:  Clin Pharmacol Ther       Date:  2003-03       Impact factor: 6.875

Review 4.  Unnecessary use of placebo controls: the case of asthma clinical trials.

Authors:  Franklin G Miller; Andrew F Shorr
Journal:  Arch Intern Med       Date:  2002 Aug 12-26

5.  Healthy children as subjects in pharmaceutical research.

Authors:  Gideon Koren
Journal:  Theor Med Bioeth       Date:  2003

6.  Phase I research and the meaning of direct benefit.

Authors:  Lainie Ross
Journal:  J Pediatr       Date:  2006-07       Impact factor: 4.406

7.  Nontherapeutic research with children: the Ramsey versus McCormick debate.

Authors:  Albert R Jonsen
Journal:  J Pediatr       Date:  2006-07       Impact factor: 4.406

8.  Ethical concerns regarding guidelines for the conduct of clinical research on children.

Authors:  S D Edwards; M J McNamee
Journal:  J Med Ethics       Date:  2005-06       Impact factor: 2.903

9.  Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial.

Authors:  John McIntyre; Sue Robertson; Elizabeth Norris; Richard Appleton; William P Whitehouse; Barbara Phillips; Tim Martland; Kathleen Berry; Jacqueline Collier; Stephanie Smith; Imti Choonara
Journal:  Lancet       Date:  2005 Jul 16-22       Impact factor: 79.321

  9 in total
  6 in total

1.  Do U.S. regulations allow more than minor increase over minimal risk pediatric research? Should they?

Authors:  David Wendler
Journal:  IRB       Date:  2013 Nov-Dec

Review 2.  Design and conduct of early phase drug studies in children: challenges and opportunities.

Authors:  Michael Rieder; Daniel Hawcutt
Journal:  Br J Clin Pharmacol       Date:  2016-08-08       Impact factor: 4.335

Review 3.  Framework conditions facilitating paediatric clinical research.

Authors:  Anne-Laure Knellwolf; Stéphane Bauzon; Ornella Della Casa Alberighi; Irja Lutsar; Ernö Bácsy; Deborah Alfarez; Pietro Panei
Journal:  Ital J Pediatr       Date:  2011-02-23       Impact factor: 2.638

4.  Clinical trials involving cats: what factors affect owner participation?

Authors:  Margaret E Gruen; Katrina N Jiamachello; Andrea Thomson; B Duncan X Lascelles
Journal:  J Feline Med Surg       Date:  2014-06-17       Impact factor: 2.015

5.  Views of adolescents and parents on pediatric research without the potential for clinical benefit.

Authors:  David Wendler; Emily Abdoler; Lori Wiener; Christine Grady
Journal:  Pediatrics       Date:  2012-09-10       Impact factor: 7.124

Review 6.  Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report.

Authors:  Diane K Wherrett; Jane L Chiang; Alan M Delamater; Linda A DiMeglio; Stephen E Gitelman; Peter A Gottlieb; Kevan C Herold; Daniel J Lovell; Trevor J Orchard; Christopher M Ryan; Desmond A Schatz; David S Wendler; Carla J Greenbaum
Journal:  Diabetes Care       Date:  2015-10       Impact factor: 19.112

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.